Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 48: 1106-1109, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bairaktari, E.
Right arrow Articles by Elisaf, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bairaktari, E.
Right arrow Articles by Elisaf, M.
Related Collections
Right arrow General Clinical Chemistry
Right arrow Other Areas of Clinical Chemistry
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2002;48:1106-1109.)
© 2002 American Association for Clinical Chemistry, Inc.


Technical Briefs

Rhabdomyolysis-related Renal Tubular Damage Studied by Proton Nuclear Magnetic Resonance Spectroscopy of Urine

Eleni Bairaktari1a, Konstantin Seferiadis1, George Liamis2, Nikolaos Psihogios1, Orestes Tsolas1 and Moses Elisaf2

1 Laboratory of Biochemistry and
2 Department of Internal Medicine, University Hospital, University of Ioannina, Medical School, 455 00 Ioannina, Greece

aauthor for correspondence; fax 30-6510-99418, e-mail ebairakt@cc.uoi.gr

The first 300 words of the full text of this article appear below.

Rhabdomyolysis is a common clinical and laboratory syndrome, resulting from skeletal muscle injury, that leads to the release of potentially toxic muscle cell contents, specifically myoglobin, into the plasma (1)(2). Rhabdomyolysis can be induced by many different mechanisms and has been implicated as a major cause of acute renal failure. However, when correct treatment is provided, it is usually reversible. Acute tubular necrosis after rhabdomyolysis does not always appear to parallel the degree of muscle damage, but it may be related to other factors that potentiate the effects of myoglobinuria, such as hypotension, acidosis, and volume depletion. The pathophysiology of the renal injury is not fully understood, but it probably includes a combination of hypoperfusion/ischemia, iron tubular cytotoxicity, and cast formation potentially leading to proximal tubular necrosis and acute renal failure.

The combination of fibrates plus 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) is an effective and generally well-tolerated treatment for high-risk patients with mixed dyslipidemias, and side effects, mainly hepatic and muscular disorders, are rare. However, when they do occur, muscular damage may be severe, leading to rhabdomyolysis (3)(4).

High-resolution proton nuclear magnetic resonance (1H-NMR) spectroscopy is a nondestructive and noninvasive technique that can provide complete structural analysis of a wide range of organic molecules in complex mixtures. NMR spectroscopy has been used for the detection of low-molecular-weight metabolites present in biological fluids as a result of changes in physiologic status, toxic insult, or disease processes (5). NMR provides quantitative information on the low-molecular-weight metabolites present in the specimen studied and allows the detection of unexpected constituents related to disease or tissue damage. Urinalysis by NMR spectroscopy has led to detailed investigation of the excretion pattern in various physiologic and pathologic situations, such as inborn errors of metabolism, organ transplantation, and . . . [Full Text of this Article]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.